title: Excellent results with clorazepate in recalcitrant childhood epilepsies.
abstract: Eleven children with severe incapacitating generalized seizures were treated with sodium valproate and clorazepate and responded with a marked decrease in seizure frequency. Three children received clorazepate alone, either because of valproate toxicity or because of parental concern over side effects. These children, 5 males and 6 females, ranged in age from 3 to 17 years. They manifested normal to severely retarded intelligence. Although valproate levels were in the therapeutic range, seizure control was inadequate. When clorazepate was added to valproate therapy a marked reduction in seizure frequency occurred within 24 hours and became optimal within 48 to 72 hours. Side effects were minimal with the exception of a nocturnal generalized tonic-clonic seizure in a single patient. Three children were withdrawn from therapy after a year because of recurrent seizures. One patient was restarted on therapy after 6 months and seizure control improved. Clorazepate may be a useful adjunct in the treatment of primary generalized seizures in children.
authors.affiliation: John F. Kennedy Institute, Baltimore, MD 21205.
authors.forename: S
authors.initials: S
authors.lastname: Naidu
authors.forename: G
authors.initials: G
authors.lastname: Gruener
authors.forename: P
authors.initials: P
authors.lastname: Brazis
mesh_terms: D000293:Adolescent; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003009:Clorazepate Dipotassium / Q000627:therapeutic use*; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies
chemical_list: D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium